Multicenter trial of low‐dose paclitaxel in patients with advanced AIDS‐related Kaposi sarcoma

Abstract

Paclitaxel given every 2 weeks induces major tumor regression in the majority of patients with advanced KS who failed to respond to previous systemic chemotherapy. Paclitaxel is associated with significant improvement in quality of life with acceptable toxicity and should be considered as an effective treatment option for patients with advanced KS.